Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fulltext

Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fulltext

Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fulltext

Dr Judith Boer on lymphoblastic leukaemia in children

Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology, and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.

Share Dr Judith Boer on lymphoblastic leukaemia in children

Sign up to save your podcasts

Dr Judith Boer on lymphoblastic leukaemia in children

Dr Judith Boer on lymphoblastic leukaemia in children